Significance of synaptic connectivity reduction for pathogenesis, clinical picture and course of schizophrenia;Znaczenie redukcji sieci poła̧czeń synaptycznych dla patogenezy, obrazu klinicznego i przebiegu schizofrenii

Psychiatria Polska

Volumn 37, Issue 6, 2003, Pages 951-964

  Rabe Jabłońska, Jolanta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Schizophrenia; Synaptic connectivity

Indexed keywords

ARTICLE; CLINICAL FEATURE; DISEASE COURSE; HEREDITY; MYELINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PATHOGENESIS; SCHIZOPHRENIA; WHITE MATTER;

BRAIN; CELL DEATH; DEMYELINATING DISEASES; HUMANS; MYELIN SHEATH; NERVE FIBERS, MYELINATED; OLIGODENDROGLIA; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 0346993210     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Mc Glashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry 2000; 57 (7): 637-648.
2. Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A, Paus T, Evans AC, Rapoport JL. Brain development during childhood and adolescence: a longitudinal MRI study. Nat. Neurosc. 1999; 2: 861-863.
3. Wright IC, Rabe-Hesketh S, Woodruff PW, Dawid AS, Murray AM, Bullmore ET. Meta-analysis of region brain volumes in schizophrenia. Am. J. Psychiatry 2000; 157: 16-25.
4. Liddle PF. Functional imaging: Schizophrenia. Brit. Med. Bull. 1996; 52: 486-494.
5. Sigmundsson T, Suckling J, Maier M., Williams S, Bullmore E, Greenwood K, Fukuda R, Ron M., Toone B. Structural abnnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am. J. Psychiatry 2001; 158: 234-243.
6. Sullivan UV, Shear PK, Lim KO, Zipursky RB, Pfefferbaum A. Cognitive and motor impairments are related to grey matter volume deficits in schizophrenia. Biol. Psychiatry 1996; 39: 234-240.
7. Lim KO, Tew W, Kushner M., Chow K, Matsumoto B, DeLisi LE. Cortical grey matter deficit in patients with first episode of schizophrenia. Am. J. Psychiatry 1997; 153, 1548-1553.
8. Sanfilipo M., Lafarque T, Rusinek H, Arena L, Loneragan C, Lautin A, Feiner D, Rotrosen J, Wilkin A. Volumetric measures of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch. Gen. Psychiatry 2000; 57: 471-480.
9. Eastwood SL, Burnet PWJ, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neurosc. 1995; 66: 309-319.
10. Benes FM. Myelination of cortical - hipocampal relays during late adolescence: anatomical correlates to the onset of schizophrenia. Schizophr. Bull. 1989; 15: 585-594.
11. Agatrz I, Andersson JL, Skare S. Abnormal brain white in schizophrenia: a diffusion tensor imaging study. Neurorep. 2001; 12: 2251-2254.
12. Haznedar M, Fallon JH, Atlas SW. MRI white matter diffusion anizotropy and PET metabolic rate in schizophrenia. Neurorep. 1998; 9: 425-430.
13. Casanova MF. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 1997; 23: 517-519.
14. Davies KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V. White matter changes in schizophrenia. Arch. Gen. Psychiatry 2002; 60: 443-456.
15. Filippi CG, Ulug AM, Ryan E, Ferrando SJ, van Gorp W. Diffusion tensor imaging of patients with HIV and normal-appearing white matter on MR images of the brain. Am. J. Neuroradiol. 2001; 22: 277-283.
16. Filippi CG, Cercignani M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurol. 2001; 56: 304-311.
17. Foong, Maler M, Barker GJ, Brocklehurst S, Miller DH, Ron MA. In vivo investigation of white matter pathology in schizophrenia with magnetization transfer imaging. J. Neurol. Neurosurg. Psychiatry 2000; 68: 70-74.
18. Gass A, Barker GJ, Kidd D, Thorpe JW., MacManus D, Brennan A, Tofts PS, Thompson AJ, McDonald WI, Miller DH. Correlation of magnetization transfer ration with clinical disability in multiple sclerosis. Ann. Neurol. 1994; 36: 62-67.
19. Shihabuddin L, Buchsbaum MS, Tang C, Brickman AM, Fleischman M, New AS, Siever LJ. Diffusion tensor imaging in schizophrenia and schizophrenia - spectrum disorders. Biol. Psychiatry 2000; 47 (supl.): 97.
20. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng KG, Griffin WS. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for "hypofrontallity" . Mol. Psychiatry 1999; 4: 39-45.
21. Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density on prefrontal area 46 in brains from schizophrenic patients: application of a 3-dimensional, streologic counting method. J. Comp. Neurol. 1998; 392: 402-412.
22. Akbarian S, Kim JJ, Potkin SG, Hatrick WP, Bunney WE Jr, Jones EG. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch. Gen. Psychiatry 1996; 53: 425-436.
23. Cotter D, Mackay D, Beasley C, Kervin R, Everall I. Reductal glial density and neuronal volume in major depression disorders and schizophrenia in the anterior cingulated cortex (abstract). Schizophr. Res. 2000; 41: 106.
24. Rivkin P, Kraut M, Barta P, Anthony J, Arria AM, Pearlson G. White matter hiperintensity volume in late-onset and early-onset schizophrenia. Int. J. Geriatr. Psychiatry 2000; 15: 1085-1089.
25. Selemon LD, Rajkowska G, Goldman-Rakic P. Abnormal high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9and occipital area. Arch. Gen. Psychiatry 1995; 52: 805-820.
26. Selemon LG, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry 1999; 45: 17-25.
27. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a post-mortem study of schizophrenia and Huntington's disease. Arch. Gen. Psychiatry 1998; 55: 215-224.
28. Montag D, Giese KP, Bartsch U, Martini R, Lang Y, Bluthmann H, Karthigsan J, Kirschner DA, Wintergerst ES, Nave KA, Zielasek J, Toyka KV, Lipp HP, Schachner M. Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin. Neuron. 1994; 13: 229-246.
29. Breitner JCS, Husain MM, Figiel GS, Krishman KRr, Boyko OB. Cerebral white matter disease in late-onset paranoid psychoses. Biol. Psychiatry 1990; 28: 266-274.
30. Ito R, Melhem ER, Mori S, Eichler FS, Raymond GV, Moser GW. Diffusion tensor brain MR imaging in X-linked cerebral adrenoleukodystrophy. Neurol. 2001; 56: 544-547.
31. Hyde TM, Ziegler JC, Wienberger DR. Psychiatric disturbances in metachromatic leukodystrophy: Insights into the neurobiology of psychosis. Arch. Neurol. 1992; 49: 401-406.
32. Schachner M, Bartsch U. Multiple functions of the myelin-associate glycoprotein MAG in formation and maintenance of myelin. Glia 2000; 29: 145-160.
33. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostikov V, Rachmanova. Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 2001; 55: 597-610.
34. Weiss MD, Hammer J, Quarles RH. Oligodendrocytes in aging mice lacking myelin-associated glycoprotein are dystrophic but not apoptic. J. Neurosc. Res. 2000; 62: 772-780.
35. Barres BA, Raff MC. Proliferation of oligodendrocyte precursor cells depends on electrical activity of axons. Nature 1993; 361: 258-259.
36. Furukawa K, Fu W, Li Y, Witke W, Kawiatkowski DJ, Yin HL, Mattson MP. The actin-severing protein gelsolin modulates calcium channel and NMDA receptor activities and vulnerability to exictotoxicity in hippocampal neurons. J. Neurosc. 1997; 17: 8178-8186.
37. Bartsch U. Myelination and axonal regeneration in the cental nervous system of mice deficient in the myelina-associated glycoprotein. J. Neurocytol. 1996; 25: 303-313.
38. Bergles DE, Roberts JD, Somogyi P, Jahr CE. Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. Nature 2000; 405: 167-191.
39. Sanches-Gomez MV, Matute C. AMPA and kainate receptors each mediate excitotoxicity in oligodendrocyty cultures. Neurobiol. Dis. 1999; 6: 475-485.
40. Lovinger DM, McCool BA. Metabotropic glutamate receptor - mediated presynaptic depression at cortocostratial synapses involved mGluR2or 3. J. Neurophysiol. 1995; 17: 1076-1083.
41. Matute C, Alberdi E, Domeroq M., Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez NV. The link between excitotoxic oligodendrial death and demylinating diseases. Trends Neurosc. 2001; 24: 224-230.
42. Buchsbaum MS, Tang CY, Peled S, Gudbjardsson H, Lu D, Hazlett EA, Downhill J, Burnashev N. Calcium permeabulity of glutamate gated channels in the central nervous system. Curr. Op. Neurobiol. 1996; 6: 311-317.
43. Moghaddam B, Adams BW, Verma A, Daly D. Activation of glutamateric neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blocade to dopaminergic and cognitive disruptions associated with prefrontal cortex. J. Neurosc. 1997; 17: 2921-2927.
44. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor in rats. Science 1889; 281: 1340-1352.
45. Olney JW., Labruyere J, Wang G, Wozniak DF, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 2001; 254: 1360-1362.
46. Benes FM, Vincent SL, Marie A, Khan Y. Up-regilation of GABA A receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neurosc. 1996; 75: 1021-1031.